LOGIN  |  REGISTER
Recursion
C4 Therapeutics

LevelJump Healthcare Announces Telehospital Canada Development Begins in Partnership with 247 Labs

August 16, 2023 | Last Trade: C$0.05 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - August 16, 2023) - LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("LevelJump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that it has begun the development process for Telehospital Canada in collaboration with the Web and Mobile App maker 247 Labs Inc.

Telehospital Canada is a digital health platform that leverages adopting technologies to provide remote urgent care and emergency room consultation services, ensuring accessible and high-quality healthcare for individuals regardless of their geographical location.

In a study by INSPIRE Primary Health Care, it was found that 2.2 million Ontario residents alone are without a family doctor. LevelJump hopes to help close this significant gap and ensure all Canadians have access to the critical care they deserve.

The digital consultation services are designed to improve accessibility to quality care and provide solutions for overcrowded ER rooms, resulting in reduced wait times for patients and quicker turnaround time for doctors. This service will be delivered on a PIPEDA and HIPPA-Compliant Cloud System.

Telehospital Canada will offer several online, mobile and at home solutions for Canadians while being backed up by in person physician consultation, when necessary, at JUMP's physical urgent care locations and diagnostic imaging centers. This includes JUMP's new central Toronto location at Yonge-Shepard that is set to open later this year.

LevelJump's partnership with 247 Labs exemplifies our on-going commitment to find innovative and enhanced solutions for improving healthcare for all Canadians. The Award-Winning 247 Labs is run by Azwar Khalid, CEO. The project will be supported by the Senior Client Advisor, Boris Dehtiar, and will be driven by the Project Manager, Medhat Fayed, alongside the rest of the 247 Labs team. "We at 247 Labs, are excited to create enhanced healthcare experiences for JUMP, aiming to provide improvements that will positively impact the lives of all Canadians. For more information about us please visit our website: https://247labs.com/."

"After months of intricate planning, we are very excited to begin the long-awaited development of Telehospital Canada," said CEO, Mitch Geisler. "We are eager to continue to deliver vital healthcare solutions to Canadians, all while maintaining the utmost standard of care. Our goal for Telehospital is driven by our mission to enhance the healthcare experience for both patients and doctors, while doing our part in alleviating the stress and backlog burdening the Canadian healthcare system."

Telehospital Canada is expected to launch in the early months of 2024, accessible via the following link www.telehospitalcanada.ca.

About LevelJump Healthcare

LevelJump Healthcare Corp., (TSXV: JUMP) provides telehealth solutions to client hospitals and imaging centers through its Teleradiology division, as well as in person radiology services through its IHF's (Independent Healthcare Facilities). JUMP focuses primarily on critical care for urgent and emergency patients, establishing integral relationships in the communities we serve.

ON BEHALF OF THE BOARD OF DIRECTORS OF
LEVELJUMP HEALTHCARE CORP.

Mitchell Geisler
Chief Executive Officer

Caitlin-Robyn Densmore
Investor Relations Manager
This email address is being protected from spambots. You need JavaScript enabled to view it.
(437) 214-1568

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, considering the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).

Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction.

Recursion

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB